CENTEK(SZ:000931)2021-08-25 16:00Financial Performance - The company's operating revenue for the reporting period was ¥951,617,787.16, representing a 24.40% increase compared to ¥764,975,280.04 in the same period last year[21]. - The net profit attributable to shareholders was ¥15,241,899.13, up 25.74% from ¥12,121,740.41 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥10,904,878.35, reflecting a 34.08% increase from ¥8,133,093.12 in the previous year[21]. - The basic earnings per share rose to ¥0.0202, a 25.47% increase from ¥0.0161 in the same period last year[21]. - The company achieved a consolidated revenue of 952 million yuan, representing a year-on-year growth of 24.40%[44]. - The net profit attributable to shareholders reached 15.24 million yuan, an increase of 25.74% compared to the previous year[44]. - The pharmaceutical and health products business generated a revenue of 668 million yuan, growing by 15.37% year-on-year, accounting for 70.17% of the total consolidated revenue[45]. Cash Flow and Assets - The net cash flow from operating activities decreased by 50.99% to ¥54,922,062.53, down from ¥112,060,303.68 in the same period last year[21]. - The total assets at the end of the reporting period were ¥3,386,905,834.74, a decrease of 1.97% from ¥3,455,089,205.24 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 0.90% to ¥1,714,702,365.49 from ¥1,699,471,784.03 at the end of the previous year[21]. - The company's cash and cash equivalents decreased by 17.40% to a net increase of -¥90,350,713.27[60]. - The company's total financial assets amounted to 8,964,143.51, with no significant changes in measurement attributes during the reporting period[71]. Research and Development - The main business areas include biomedicine, personal care products, and elderly care services, with a focus on R&D and sales of various pharmaceutical forms[28]. - The company operates three R&D centers in Beijing, Shandong, and Heilongjiang, focusing on independent and collaborative research and development[35]. - The company is actively exploring the biopharmaceutical field and promoting the development of innovative drugs to enhance market competitiveness[42]. - The company has entered the registration process for several drugs, including Zhimu Saponin BⅡ and capsules, which are in Phase I clinical trials for treating vascular dementia[30]. - The company submitted the second supplementary response for Oxycodone Hydrochloride to the CDE on March 31, 2021, and is currently undergoing production process information approval[30]. Marketing and Sales - The company has established a comprehensive marketing system covering hospitals, retail pharmacies, and grassroots medical institutions, while also exploring online sales[35]. - The company has established a professional team for market promotion and access, enhancing brand influence and market penetration[37]. - The company is focusing on the integration of medical care and elderly care services, accelerating the development of the "Internet + Elderly Care" business model[38]. - The company launched two new products: "Probiotic Vitamin C Oral Tablets" and "Oral Ulcer Film," expanding its oral healthcare product line into three categories: prevention, treatment, and care[47]. - The company’s "Huasu Yuchuang" mouthwash won the "Most Popular Star Product Award" among pharmacies, highlighting its successful marketing strategy in the health product sector[47]. Legal and Compliance - The company reported a lawsuit involving a claim for 6.41 million yuan and interest of 410,000 yuan, totaling 6.41 million yuan, with an expected difficulty in recovering the amount[133]. - The company is pursuing a claim against Beijing Zhongyu Real Estate Development Co., Ltd. for a total of 6.581 million yuan, which includes a principal amount of 6 million yuan and interest[133]. - The company has ongoing litigation with Blue Ocean Company, seeking a compensation of approximately 39.71 million yuan, which is currently under execution[133]. - The company has recorded a provision for expected liabilities amounting to 28.05 million yuan related to ongoing litigation[134]. - The company is actively managing its legal risks and financial liabilities associated with ongoing lawsuits and claims[135]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[107]. - The total chemical oxygen demand (COD) discharge was 1.82 tons for the half-year, with no exceedance of discharge standards[107]. - The company has established a comprehensive environmental management system, ensuring all pollutants are treated to meet the required standards, with no environmental issues reported during the reporting period[121]. - The company has passed the clean production report review in April 2021, demonstrating commitment to environmental sustainability[118]. - All pollutants from Beijing Huasu Pharmaceutical Co., Ltd. were within discharge standards during the reporting period[115]. Future Outlook - Future guidance suggests a targeted revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[88]. - The company plans to enhance its technology consulting services, aiming for a 15% increase in service-related revenue[88]. - The company is exploring opportunities in the healthcare and wellness sectors, with a focus on developing health-related products and services[88]. - The management has outlined a strategy to reduce operational losses by 10% in the upcoming quarters through cost optimization measures[88]. - The company is focusing on expanding its market presence through strategic partnerships and acquisitions in the healthcare sector[88].